))
#2 - A biomaterial-based vaccine
Manage episode 429175496 series 3586580
Contenuto fornito da Accelerating Cancer Immunotherapy Research (ACIR). Tutti i contenuti dei podcast, inclusi episodi, grafica e descrizioni dei podcast, vengono caricati e forniti direttamente da Accelerating Cancer Immunotherapy Research (ACIR) o dal partner della piattaforma podcast. Se ritieni che qualcuno stia utilizzando la tua opera protetta da copyright senza la tua autorizzazione, puoi seguire la procedura descritta qui https://it.player.fm/legal.
In this 2nd episode, our co-hosts discuss the use of a macro-scale material to co-deliver GMCSF and CpG, both APC stimulating agents, as well as AML antigens to kill AML cells.
GUEST: Alex Najibi is now a postdoctoral fellow at Harvard School of Engineering and Applied Sciences, studying bioengineering in David Mooney's lab.
Original study => https://pubmed.ncbi.nlm.nih.gov/31937942/
Thanks for listening! Let’s stay in touch:
- Tweet us at @ImmunoTalks
- Share our episodes on LinkedIN and Instagram
- Email us at contact@acir.org
Capitoli
1. #2 - A biomaterial-based vaccine (00:00:00)
2. Background about the study (00:00:29)
3. GUEST: Alex Najibi (00:05:30)
3 episodi
Condividi
